Association between circulating ANGPTL levels and general medical status (n = 800).

<p>A generalized linear model was used. All variables listed were included in the model. ANGPTL, Angiopoietin-like protein; β, regression coefficient; 95% CI, 95% confidence interval; P, probability; and CKD, chronic kidney disease.</p

Baseline characteristics of study population subjects.

<p>Data is shown as the median or interquartile range (IQR); BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA_1C, hemoglobin A_1C; LDL, low-density lipoprotein; HDL, high-density lipoprotein; AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma-glutamyltransferase; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; and hs-CRP, high-sensitivity C reactive protein.</p

Association between circulating ANGPTL4 levels and laboratory tests relevant to impaired glycometabolism, hepatic impairment or inflammation (n = 800).

<p>A generalized linear model was used. To evaluate HbA_1C or glucose, each covariate was adjusted by all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193731#pone.0193731.t003" target="_blank">Table 3</a>, minus the impaired glyometabolism category. To evaluate AST, ALT, or GGT, each covariate was adjusted by all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193731#pone.0193731.t003" target="_blank">Table 3</a>, minus the hepatic impairment category. To evaluate hs-CRP, each covariate was adjusted by all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193731#pone.0193731.t003" target="_blank">Table 3</a>, minus inflammation. β, regression coefficient; 95% CI, 95% confidence interval; HbA_1C, hemoglobin A_1C; AST, aspartate transaminase; ALT, alanine transaminase; GGT, Gamma-glutamyltransferase; and hs-CRP, high sensitivity C reactive protein.</p

Association between circulating ANGPTL3 levels and lab values relevant to hepatic impairment or inflammation (n = 800).

<p>A generalized linear model was used. To evaluate AST, ALT or GGT, covariates were adjusted by all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193731#pone.0193731.t003" target="_blank">Table 3</a>, minus the hepatic impairment category. To evaluate hs-CRP, covariates were adjusted by all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193731#pone.0193731.t003" target="_blank">Table 3</a>, minus the inflammation category. β, regression coefficient; 95% CI, 95% confidence interval; AST, aspartate transaminase; ALT, alanine transaminase; GGT, gamma-glutamyltransferase; and hs-CRP, high sensitivity C reactive protein.</p

Baseline characteristics of subjects of study population.

<p>Data is shown as the percentage or 95% confidence interval (95%CI). CKD, chronic kidney disease.</p

Association between circulating ANGPTL8 levels and laboratory tests relevant to obesity, impaired glycometabolism, or dyslipidemia (n = 800).

<p>A generalized linear model was used. To evaluate BMI, each covariate was adjusted by all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193731#pone.0193731.t003" target="_blank">Table 3</a>, minus obesity. To evaluate HbA1C or glucose, each covariate was adjusted by all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193731#pone.0193731.t003" target="_blank">Table 3</a>, minus the impaired glycometabolism catergory. To evaluate HDL, LDL or triglyceride, each covariate was adjusted by all variables listed in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0193731#pone.0193731.t003" target="_blank">Table 3</a>, minus the dyslipidemia category. BMI, body mass index; HbA1C, hemoglobin A1C; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; TG, triglyceride; β, regression coefficient; and 95% CI, 95% confidence interval.</p

Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: A cross-sectional study - Fig 1

<p>Distribution of circulating levels of (A) ANGPTL3, (B) ANGPTL4, and (C) ANGPTL8. IQR, Interquartile range (n = 988).</p

BABR increase energy expenditure.

<p>Hematoxylin and eosin (HE) stained epWAT (A) and BAT (B) sections of C57BL/6J animals treated with control or HF diet when indicated combined with colestimide or CA as specified in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0038286#pone-0038286-g001" target="_blank">Fig. 1</a>. Scale bar, 50 µm. (C) BAT analysis by transmission electron microscopy. (D) Averaged O₂ consumption (VO₂) and CO₂ production (VCO₂) as measured by indirect calorimetry in mice on the different diets as indicated. Data are expressed as the mean +/− SEM (n = 5–6). * (<i>P</i><0.05) or ** (<i>P</i><0.01) versus F.</p

Bile acid composition in the enterohepatic organs and serum.

<p>Bile acid composition in the enterohepatic organs and serum of C57BL/6J fed with high fat diet (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0038286#pone-0038286-g001" target="_blank">Fig. 1A</a>) after treatment with colestimide or CA. Undefined abbreviations are: G, glycol; T, tauro; CD, chenodeoxy; D, deoxy; H, hyo; HD, hyodeoxy; UD, ursodeoxy; L, litho; M, muri.</p

BA and BABR improve metabolic control in DIO C57BL/6J mice model.

<p>(A) Body weight, food intake and TG absorption (B) Liver, epididymal WAT (epWAT), and BAT weight change of C57BL/6J mice during 96 days on different diets. Ch stands for chow, F denotes HF diet, FCOL denotes HF diet+2.0% w/w colestimide and FB denotes HF diet+0.5% w/w CA. (C) Serum levels of TG, T-C, LDL-C, glucose and insulin in C57BL/6J mice on the indicated treatments. (D) Glucose levels during OGTT and IPITT in the different treatment groups (AUC is depicted in the inset). The OGTT were performed after an overnight fast after 9 weeks of administration. Glucose was administered by gavage at a dose of 2 g/kg. The IPITT were performed after 4 h fast after 10 weeks of administration. Insulin was injected at a dose of 0.75 U/kg. Data are expressed as the mean +/− SEM (n = 5–6). * (<i>P</i><0.05) or ** (<i>P</i><0.01) versus F.</p